Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising these fully humanized antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in these methods.
Type:
Grant
Filed:
April 11, 2016
Date of Patent:
February 20, 2018
Assignee:
Kymab Limited
Inventors:
Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Dominik Spensberger, Hui Liu, Jasper Clube
Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
Type:
Application
Filed:
April 6, 2017
Publication date:
December 21, 2017
Applicant:
Kymab Limited
Inventors:
Jamie Campbell, Nikole Sandy Nee Waddell, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
Abstract: The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
Type:
Application
Filed:
June 1, 2017
Publication date:
November 9, 2017
Applicant:
Kymab Limited
Inventors:
Volker GERMASCHEWSKI, Igor Theurl, Martin Yateman, Jasper Clube, Steve Arkinstall
Abstract: The invention provides antibodies and fragments thereof which bind to human Nav1.7, as well as nucleic acids, vectors, host cells and hybridomas for making the same. Further provided are pharmaceutical compositions for use in treating, preventing and/or reducing the risk of a NAV1.7-mediated conditions or diseases, such as pain, inflammation, and metabolic/chronic diseases. The invention additionally provides methods of generating an antibody against a NAV protein of interest.
Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising the antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in the methods.
Type:
Grant
Filed:
March 18, 2013
Date of Patent:
October 17, 2017
Assignee:
Kymab Limited
Inventors:
Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Dominik Spensberger, Hui Liu, Jasper Clube
Abstract: The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention.
Type:
Grant
Filed:
May 2, 2013
Date of Patent:
October 10, 2017
Assignee:
Kymab Limited
Inventors:
Allan Bradley, Glenn Friedrich, E-Chiang Lee, Mark Strivens, Nicholas England
Abstract: The invention provides improved non-human vertebrates and non-vertebrate cells capable of expressing antibodies comprising human variable region sequences. The present invention is directed to the provision of long HCDR3s from non-human vertebrates and cells. The present invention is also directed to the provision of novel V, D and J pairings in immunoglobulin heavy and light chain loci. Novel, biased antibody diversities and potentially expanded diversities are provided. The invention also provides for novel and potentially expanded diversity or diversity that is biased towards variable gene usage common to antibodies useful for treating and/or preventing certain diseases or conditions, such as infectious diseases. The invention also provides methods of generating antibodies using such vertebrates, as well as the antibodies per se, therapeutic compositions thereof and uses.
Type:
Grant
Filed:
March 19, 2014
Date of Patent:
October 10, 2017
Assignee:
Kymab Limited
Inventors:
Glenn Friedrich, E-Chiang Lee, Jasper Clube, Nicholas England
Abstract: The invention relates to an approach for introducing one or more desired insertions and/or deletions of known sizes into one or more predefined locations in a nucleic acid (e.g., in a cell or organism genome). They developed techniques to do this either in a sequential fashion or by inserting a discrete DNA fragment of defined size into the genome precisely in a predefined location or carrying out a discrete deletion of a defined size at a precise location. The technique is based on the observation that DNA single-stranded breaks are preferentially repaired through the HDR pathway, and this reduces the chances of indels (e.g., produced by NHEJ) in the present invention and thus is more efficient than prior art techniques. The invention also provides sequential insertion and/or deletions using single- or double-stranded DNA cutting.
Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
Type:
Grant
Filed:
November 17, 2016
Date of Patent:
April 11, 2017
Assignee:
Kymab Limited
Inventors:
Jamie Campbell, Nikole Sandy, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
Type:
Grant
Filed:
July 15, 2016
Date of Patent:
February 14, 2017
Assignee:
Kymab Limited
Inventors:
Jamie Campbell, Nikole Sandy, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher